COVID-19 Vaccines for 5 to 11 Year Olds Appear on the Way
Enough of the Pfizer/BioNTech vaccine has been secured to offer vaccinations for everyone in this age group.
A rollout of a COVID-19 vaccine for children ages 5 to 11 could begin early next month. The Biden Administration announced today it had secured enough of the Pfizer/BioNTech vaccine for the US pediatric population to roll out vaccinations to 5 to 11-year-old children.
The White House issued a statement saying that it plans to “ensure that, if a vaccine is authorized for children ages 5-11, it is quickly distributed and made conveniently and equitably available to families across the country.”
The timeline for upcoming meetings by the Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) have been set and both will discuss and review data regarding this age group. The FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting is set for October 26 and open to the public.
The CDC is planning back-to-back meetings on November 2-3 to weigh the FDA’s recommendations.
Assuming the FDA approves the Pfizer-BioNTech vaccine in this age group and the CDC also recommends it, the rollout for vaccinations in children ages 5 to 11 years could begin in early November.
“Millions of adolescents ages 12-17 have been safely vaccinated, and we know vaccines work,” the White House said in the statement. “Fully vaccinated individuals are 10 times less likely to be hospitalized with COVID-19 and have a high degree of protection, including against the Delta variant. The consequences of a pediatric COVID-19 case can be serious and potentially last months.”
The announcement comes as evidence mounts that not only not only can pediatric patients of all ages carry high viral loads of SARS-CoV-2, but they can also serve as a means for the virus to mutate.
A study published October 14 in the Journal of Infectious Diseases investigators with Massachusetts General Hospital write that “symptomatic and asymptomatic children can carry high quantities of live, replicating SARS-CoV-2, creating a potential reservoir for transmission and evolution of genetic variants. As guidance around social distancing and masking evolves following vaccine uptake in older populations, a clear understanding of SARS-CoV-2 infection dynamics in children is critical for rational development of public health policies and vaccination strategies to mitigate the impact of COVID-19.”
This article first appeared inContagion®.
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.
